2023-07-27 06:39:18 ET
- Boston Scientific press release ( NYSE: BSX ): Q2 Non-GAAP EPS of $0.53 beats by $0.04 .
- Revenue of $3.59B (+10.8% Y/Y) beats by $90M .
- MedSurg: 9.0 percent reported, 9.6 percent operational and 8.8 percent organic
- Cardiovascular: 12.2 percent reported, 13.4 percent operational and organic
- Achieved the following net sales growth in each region, compared to the prior year period:
- U.S.: 9.1 percent reported and operational
- EMEA (Europe, Middle East and Africa): 9.6 percent reported and 9.3 percent operational
- APAC (Asia-Pacific): 18.0 percent reported and 24.5 percent operational
- LACA (Latin America and Canada): 16.9 percent reported and 17.4 percent operational
- Emerging Markets: 18.8 percent reported and 24.2 percent operational
For further details see:
Boston Scientific Non-GAAP EPS of $0.53 beats by $0.04, revenue of $3.59B beats by $90M